
Direct-to-Consumer (DTC) Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomic Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) chips,
Description
Direct-to-Consumer (DTC) Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomic Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) chips, Whole Genome Sequencing (WGS)), By Distribution Channel (Online Platforms, Over-the-Counter), Industry Analysis Report, Regional Outlook, Growth Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2028
The direct-to-consumer genetic testing market is set to witness lucrative expansion through 2028 owing to rising prevalence of genetic diseases across the globe. In addition, growing public acceptance and surging awareness pertaining to genetic testing, coupled with mounting demand for personalized services without direct involvement of a healthcare provider, are anticipated to further drive the growth of the industry over the forecast timeline.
Recently, technological advancements have created massive opportunities for product penetration. Moreover, increasing number of chronic diseases, along with the launch of personalized testing kits on online platforms, has also positively influenced the product landscape.
Notably, industry players have been focusing on product innovation to gain a competitive edge in the direct-to-consumer genetic testing market, thereby fueling business growth. For instance, in January 2022, 23andMe, a major consumer genetics firm, received 510(k) clearance from the U.S. FDA for a test that detects a hereditary marker for prostate cancer. The test gives information on the presence of the G84E mutation in the user’s HOXB13 gene, which has been shown to increase the risk of prostate cancer.
Overall, the direct-to-consumer genetic testing market has been segregated in terms of test type, technology, distribution channel, and region. With reference to test type, the market has been classified into predictive testing, carrier testing, skincare testing, ancestry and relationship testing, and nutrigenomic testing. Among these, the nutrigenomic testing segment garnered a revenue of over USD 315 million in 2021 and is poised to exhibit sturdy growth over 2022-2028. The growth of this segment is mainly due to increasing awareness about health and wellness in people.
On the basis of technology, the direct-to-consumer genetic testing market has been segmented into targeted analysis, whole genome sequencing (WGS), and single nucleotide polymorphism (SNP) chips. The targeted analysis technology segment is likely to depict a CAGR of approximately 14.5% through the analysis timeframe owing to notable advancements in the technology for the diagnosis of different diseases.
Based on distribution channel, the market has been bifurcated into over-the-counter and online platform. In 2021, the online platform segment reached a valuation of nearly USD 1 billion and is set to observe considerable growth over the forecast period. Ease of conducting online business with a wide range of products is primed to drive segmental growth in the coming years.
From the regional point of view, the Latin America direct-to-consumer genetic testing industry accounted for a market share of around 10.5% in 2021 and is primed to witness robust growth through 2028. Soaring public awareness regarding direct-to-consumer genetic testing in the region is estimated to foster market outlook.
The direct-to-consumer genetic testing market is set to witness lucrative expansion through 2028 owing to rising prevalence of genetic diseases across the globe. In addition, growing public acceptance and surging awareness pertaining to genetic testing, coupled with mounting demand for personalized services without direct involvement of a healthcare provider, are anticipated to further drive the growth of the industry over the forecast timeline.
Recently, technological advancements have created massive opportunities for product penetration. Moreover, increasing number of chronic diseases, along with the launch of personalized testing kits on online platforms, has also positively influenced the product landscape.
Notably, industry players have been focusing on product innovation to gain a competitive edge in the direct-to-consumer genetic testing market, thereby fueling business growth. For instance, in January 2022, 23andMe, a major consumer genetics firm, received 510(k) clearance from the U.S. FDA for a test that detects a hereditary marker for prostate cancer. The test gives information on the presence of the G84E mutation in the user’s HOXB13 gene, which has been shown to increase the risk of prostate cancer.
Overall, the direct-to-consumer genetic testing market has been segregated in terms of test type, technology, distribution channel, and region. With reference to test type, the market has been classified into predictive testing, carrier testing, skincare testing, ancestry and relationship testing, and nutrigenomic testing. Among these, the nutrigenomic testing segment garnered a revenue of over USD 315 million in 2021 and is poised to exhibit sturdy growth over 2022-2028. The growth of this segment is mainly due to increasing awareness about health and wellness in people.
On the basis of technology, the direct-to-consumer genetic testing market has been segmented into targeted analysis, whole genome sequencing (WGS), and single nucleotide polymorphism (SNP) chips. The targeted analysis technology segment is likely to depict a CAGR of approximately 14.5% through the analysis timeframe owing to notable advancements in the technology for the diagnosis of different diseases.
Based on distribution channel, the market has been bifurcated into over-the-counter and online platform. In 2021, the online platform segment reached a valuation of nearly USD 1 billion and is set to observe considerable growth over the forecast period. Ease of conducting online business with a wide range of products is primed to drive segmental growth in the coming years.
From the regional point of view, the Latin America direct-to-consumer genetic testing industry accounted for a market share of around 10.5% in 2021 and is primed to witness robust growth through 2028. Soaring public awareness regarding direct-to-consumer genetic testing in the region is estimated to foster market outlook.
Table of Contents
190 Pages
- Chapter 1 Methodology
- 1.1 Methodology
- 1.2 Market definitions
- 1.3 Forecast parameters
- 1.4 Data sources
- 1.4.1 Secondary
- 1.4.1.1 Paid sources
- 1.4.1.2 Unpaid sources
- 1.4.2 Primary
- Chapter 2 Executive Summary
- 2.1 Direct-to-consumer genetic testing industry 360 degree synopsis, 2017 - 2028
- 2.1.1 Business trends
- 2.1.2 Test type trends
- 2.1.3 Technology trends
- 2.1.4 Distribution channel trends
- 2.1.5 Regional trends
- Chapter 3 Direct-to-Consumer Genetic Testing Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2017 - 2028
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Rising public awareness regarding DTC genetic tests in North America
- 3.3.1.2 Surging income level in emerging economies
- 3.3.1.3 Increasing demand for personalized DTC genetic services in North America and Europe
- 3.3.1.4 Growing incidences of genetic disorders globally
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 High cost of DTC
- 3.3.2.2 Defects in the DTC testing
- 3.4 Growth potential analysis
- 3.4.1 By test type
- 3.4.2 By technology
- 3.4.3 By distribution channel
- 3.5 COVID-19 impact analysis
- 3.6 Regulatory landscape
- 3.7 Porter's analysis
- 3.8 Competitive landscape, 2021
- 3.8.1 Company matrix analysis, 2021
- 3.9 PESTEL analysis
- Chapter 4 Direct-To-Consumer Genetic Testing Market, By Test Type
- 4.1 Key segment trends
- 4.2 Carrier testing
- 4.2.1 Market size, by region, 2017 - 2028 (USD Million, 000' Units)
- 4.3 Predictive testing
- 4.3.1 Market size, by region, 2017 - 2028 (USD Million, 000' Units)
- 4.4 Ancestry & relationship testing
- 4.4.1 Market size, by region, 2017 - 2028 (USD Million, 000' Units)
- 4.5 Nutrigenomics testing
- 4.5.1 Market size, by region, 2017 - 2028 (USD Million, 000' Units)
- 4.6 Skincare testing
- 4.6.1 Market size, by region, 2017 - 2028 (USD Million, 000' Units)
- 4.7 Others
- 4.7.1 Market size, by region, 2017 - 2028 (USD Million, 000' Units)
- Chapter 5 Direct-To-Consumer Genetic Testing Market, By Technology
- 5.1 Key segment trends
- 5.2 Targeted analysis
- 5.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.3 Single nucleotide polymorphism (SNP) chips
- 5.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.4 Whole genome sequencing (WGS)
- 5.4.1 Market size, by region, 2017 - 2028 (USD Million)
- Chapter 6 Direct-To-Consumer Genetic Testing Market, By Distribution Channel
- 6.1 Key segment trends
- 6.2 Online platforms
- 6.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 6.3 Over-the-counter
- 6.3.1 Market size, by region, 2017 - 2028 (USD Million)
- Chapter 7 Direct-To-Consumer Genetic Testing Market, By Region
- 7.1 Key regional trends
- 7.2 North America
- 7.2.1 Market size, by country, 2017 - 2028 (USD Million, 000' Units)
- 7.2.2 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.2.3 Market size, by technology, 2017 - 2028 (USD Million)
- 7.2.4 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.2.5 U.S.
- 7.2.5.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.2.5.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.2.5.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.2.6 Canada
- 7.2.6.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.2.6.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.2.6.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.3 Europe
- 7.3.1 Market size, by country, 2017 - 2028 (USD Million, 000' Units)
- 7.3.2 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.3.3 Market size, by technology, 2017 - 2028 (USD Million)
- 7.3.4 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.3.5 Germany
- 7.3.5.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.3.5.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.3.5.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.3.6 UK
- 7.3.6.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.3.6.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.3.6.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.3.7 France
- 7.3.7.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.3.7.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.3.7.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.3.8 Italy
- 7.3.8.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.3.8.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.3.8.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.3.9 Spain
- 7.3.9.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.3.9.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.3.9.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.4 Asia Pacific
- 7.4.1 Market size, by country, 2017 - 2028 (USD Million, 000' Units)
- 7.4.2 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.4.3 Market size, by technology, 2017 - 2028 (USD Million)
- 7.4.4 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.4.5 China
- 7.4.5.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.4.5.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.4.5.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.4.6 Japan
- 7.4.6.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.4.6.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.4.6.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.4.7 India
- 7.4.7.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.4.7.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.4.7.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.4.8 South Korea
- 7.4.8.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.4.8.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.4.8.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.4.9 Australia
- 7.4.9.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.4.9.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.4.9.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.5 Latin America
- 7.5.1 Market size, by country, 2017 - 2028 (USD Million, 000' Units)
- 7.5.2 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.5.3 Market size, by technology, 2017 - 2028 (USD Million)
- 7.5.4 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.5.5 Brazil
- 7.5.5.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.5.5.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.5.5.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.5.6 Mexico
- 7.5.6.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.5.6.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.5.6.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.5.7 Argentina
- 7.5.7.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.5.7.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.5.7.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.6 Middle East & Africa
- 7.6.1 Market size, by country, 2017 - 2028 (USD Million, 000' Units)
- 7.6.2 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.6.3 Market size, by technology, 2017 - 2028 (USD Million)
- 7.6.4 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.6.5 Saudi Arabia
- 7.6.5.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.6.5.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.6.5.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.6.6 South Africa
- 7.6.6.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.6.6.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.6.6.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- 7.6.7 UAE
- 7.6.7.1 Market size, by test type, 2017 - 2028 (USD Million, 000' Units)
- 7.6.7.2 Market size, by technology, 2017 - 2028 (USD Million)
- 7.6.7.3 Market size, by distribution channel, 2017 - 2028 (USD Million)
- Chapter 8 Company Profiles
- 8.1 Strategy dashboard, 2021
- 8.2 23andMe, Inc.
- 8.2.1 Business overview
- 8.2.2 Financial data
- 8.2.3 Product landscape
- 8.2.4 Strategic outlook
- 8.2.5 SWOT analysis
- 8.3 Ancestry
- 8.3.1 Business overview
- 8.3.2 Financial data
- 8.3.3 Product landscape
- 8.3.4 Strategic outlook
- 8.3.5 SWOT analysis
- 8.4 Color Genomics
- 8.4.1 Business overview
- 8.4.2 Financial data
- 8.4.3 Product landscape
- 8.4.4 Strategic outlook
- 8.4.5 SWOT analysis
- 8.5 Easy DNA
- 8.5.1 Business overview
- 8.5.2 Financial data
- 8.5.3 Product landscape
- 8.5.4 Strategic outlook
- 8.5.5 SWOT analysis
- 8.6 Family Tree DNA
- 8.6.1 Business overview
- 8.6.2 Financial data
- 8.6.3 Product landscape
- 8.6.4 Strategic outlook
- 8.6.5 SWOT analysis
- 8.7 Full Genome Corporation Inc.
- 8.7.1 Business overview
- 8.7.2 Financial data
- 8.7.3 Product landscape
- 8.7.4 Strategic outlook
- 8.7.5 SWOT analysis
- 8.8 Helix OpCo LLC
- 8.8.1 Business overview
- 8.8.2 Financial data
- 8.8.3 Product landscape
- 8.8.4 Strategic outlook
- 8.8.5 SWOT analysis
- 8.9 Karmagenes SA
- 8.9.1 Business overview
- 8.9.2 Financial data
- 8.9.3 Product landscape
- 8.9.4 Strategic outlook
- 8.9.5 SWOT analysis
- 8.10 Living DNA Ltd.
- 8.10.1 Business overview
- 8.10.2 Financial data
- 8.10.3 Product landscape
- 8.10.4 Strategic outlook
- 8.10.5 SWOT analysis
- 8.11 Mapmygenome
- 8.11.1 Business overview
- 8.11.2 Financial data
- 8.11.3 Product landscape
- 8.11.4 Strategic outlook
- 8.11.5 SWOT analysis
- 8.12 Identigene
- 8.12.1 Business overview
- 8.12.2 Financial data
- 8.12.3 Product landscape
- 8.12.4 Strategic outlook
- 8.12.5 SWOT analysis
- 8.13 Pathway genomics
- 8.13.1 Business overview
- 8.13.2 Financial data
- 8.13.3 Product landscape
- 8.13.4 Strategic outlook
- 8.13.5 SWOT analysis
- 8.14 Genesis Healthcare Co.
- 8.14.1 Business overview
- 8.14.2 Financial data
- 8.14.3 Product landscape
- 8.14.4 Strategic outlook
- 8.14.5 SWOT analysis
- 8.15 MyHeritage
- 8.15.1 Business overview
- 8.15.2 Financial data
- 8.15.3 Product landscape
- 8.15.4 Strategic outlook
- 8.15.5 SWOT analysis
- 8.16 24 Genetics
- 8.16.1 Business overview
- 8.16.2 Financial data
- 8.16.3 Product landscape
- 8.16.4 Strategic outlook
- 8.16.5 SWOT analysis
- 8.17 The SkinDNA Company Pty Ltd
- 8.17.1 Business overview
- 8.17.2 Financial data
- 8.17.3 Product landscape
- 8.17.4 Strategic outlook
- 8.17.5 SWOT analysis
- 8.18 DNA Forensics Laboratory Pvt. Ltd.
- 8.18.1 Business overview
- 8.18.2 Financial data
- 8.18.3 Product landscape
- 8.18.4 Strategic outlook
- 8.18.5 SWOT analysis
- 8.19 DNA Diagnostic Center
- 8.19.1 Business overview
- 8.19.2 Financial data
- 8.19.3 Product landscape
- 8.19.4 Strategic outlook
- 8.19.5 SWOT analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.